Business Context and Reporting Period
This Form 8-K is a current report filed by NanoVibronix, Inc. (trading symbol: NAOV) on July 24, 2025. The filing discloses the appointment of new executive officers effective as of the report date. The registrant is incorporated in Delaware and maintains its principal executive offices in Tyler, Texas.
Key Personnel Changes
On July 24, 2025, the Board of Directors appointed Rita Silberberg to the following roles:
- Executive Vice President of Finance
- Chief Accounting Officer
- Corporate Secretary
Ms. Silberberg brings over 15 years of experience in corporate finance, legal-structural planning, and international tax strategy. Prior to joining ENvue Medical Israel Ltd. in 2022, she served as CFO at Gravity Creative Space (2013–2022) and held roles at Ernst & Young.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive appointments and employment terms.
Material Changes and Compensation
Ms. Silberberg's appointment is governed by an employment agreement dated February 12, 2025, with ENvue Medical Israel Ltd. Key compensation terms include:
- Base Salary: NIS 44,000 per month, increasing to NIS 68,750 per month upon completion of certain milestones.
- Termination: The agreement may be terminated by either party per its terms, or by ENvue for Cause with immediate effect.
- Covenants: Includes customary confidentiality and privacy provisions.
The Company expects Ms. Silberberg to enter into a standard indemnification agreement and a direct employment agreement with NanoVibronix, Inc.
Outlook and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond standard employment agreement terms. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the exact terms of the "certain milestones" required to increase Ms. Silberberg's salary to NIS 68,750 per month.
- Review the full text of the Employment Agreement (Exhibit 10.1) for detailed termination clauses and non-compete provisions.
- Confirm the execution of the anticipated direct employment agreement between Ms. Silberberg and NanoVibronix, Inc.
- Monitor future filings for the formal transition of Ms. Silberberg's role from ENvue Medical Israel Ltd. to the U.S. parent company.